ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2506

The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis

Anna Antony1, Darren Hart 2, Charlotte Cavill 3, Eleanor Korendowych 4, Neil McHugh 5, Christopher Lovell 4 and William Tillett 4, 1Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Melbourne, Victoria, Australia, 2Department of Clinical Measurement, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, 3Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, 4Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, 5University of Bath, Bath, England, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Psoriatic arthritis, psoriatic nail dystrophy and outcome measures

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Background: Longitudinal assessment of psoriatic nail dystrophy and its response to treatment is limited outside of research settings due to the complexity of existing scoring tools. The ‘Severity of Nail Psoriasis Score’ (SNAPS; previously known as the Bath Nail Score) is a simple tool developed for use in the observational setting. It assesses for the presence of 4 features of fingernail psoriasis (pitting, onycholysis, hyperkeratosis, and severe nail deformity; score 0-40). We aimed to validate this tool in an observational cohort of patients with Psoriatic Arthritis (PsA).

Methods: Methods: Consenting consecutive patients enrolled in the Bath PsA longitudinal cohort underwent photography of their fingernails. Clinical assessments included 66/68 tender and swollen joint count, Psoriasis Area and Severity Index, Leeds Enthesitis Index, Leeds Dactylitis Index, and Physician Nail Visual Acuity Scale (PhNVAS). Participants completed the Health Assessment Questionnaire-Disability Index and a Patient Nail VAS (PtNVAS). Dorsal view photographs of each fingernail were acquired using a tripod-mounted DSLR camera with macro lens. An angled mirror was positioned distally to capture the presence of hyperkeratosis. Scoring was conducted by two assessors (WT and AA) using the modified Nail Psoriasis Severity Index (mNAPSI; range 0-130) and SNAPS tools (Table 1). Timed scoring was conducted in a third of patients to assess the feasibility of both tools. Five patients were scored by both assessors at two time points to assess for inter-rater and test-retest reliability using interclass correlation coefficients (ICCs) for absolute agreement of single measures. The correlation between outcome variables was assessed using Pearson’s correlation (r) and Spearman’s rho where appropriate.

Results: Results: Nineteen consecutive patients with and 2 consecutive patients without nail involvement were included. Mean (SD) age was 55 (11.2) years and 42.9% were female. Mean (SD) mNAPSI and SNAPS scores were 24 (17.2) and 14 (8.8). Median (IQR) PhNVAS and PtNVAS were 20 (13.0-37.0) and 18 (9.5-29.3). A total of 210 nails were assessed. Nail disease was present in 90.5% of patients using either score, and in 79% of nails using SNAPS and 82.4% of nails using mNAPSI. The main nail feature contributing to this discrepancy was splinters. Mean time to score the nails per patient using the SNAPS and mNAPSI was 59 (13.0) and 136 (27.8) seconds respectively. The inter-rater and test-retest reliability of the SNAPS was 0.92-0.94 (p< 0.001) and 0.93-0.96 (p< 0.005). The inter-rater and test-retest reliability of the mNAPSI was 0.71-0.78 (p< 0.03) and 0.95-0.97 (p=0.002). There was a strong correlation between the SNAPS and mNAPSI (r=0.95, p< 0.001) (Figure 1), and a moderate correlation between the SNAPS and PhNVAS (r=0.77, p< 0.001) and PtNVAS (r=0.63, p=0.002), and the mNAPSI and PhNVAS (r=0.84, p< 0.001) and PtNVAS (r=0.64, p=0.002). The SNAPS scores did not demonstrate significant floor or ceiling effects (Figure 2).

Conclusion: Conclusion: SNAPS is feasible, reliable and demonstrates construct validity against mNAPSI for assessing psoriatic nail dystrophy. Follow-up data is needed to assess longitudinal validity.

Table 1: Nail Psoriasis Scoring Systems

Figure 1: Correlation between the mNAPSI and SNAPS

Figure 2: Histograms of Nail Scores


Disclosure: A. Antony, None; D. Hart, None; C. Cavill, AbbVie, 2, Celgene Ltd, 2, Novartis, 2, 8; E. Korendowych, None; N. McHugh, None; C. Lovell, None; W. Tillett, None.

To cite this abstract in AMA style:

Antony A, Hart D, Cavill C, Korendowych E, McHugh N, Lovell C, Tillett W. The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-severity-of-nail-psoriasis-score-snaps-is-feasible-reliable-and-demonstrates-construct-validity-against-the-mnapsi-in-an-observational-cohort-of-patients-with-psoriatic-arthri/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-severity-of-nail-psoriasis-score-snaps-is-feasible-reliable-and-demonstrates-construct-validity-against-the-mnapsi-in-an-observational-cohort-of-patients-with-psoriatic-arthri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology